Analysts' Actions: BSX CNK DELL LULU VZ
Research In Motion (RIMM) was downgraded at Canaccord to sell. Valuation call, based on a $10 price target. Core fundamentals remain soft, Canaccord said.
Teva Pharmaceuticals (TEVA) was downgraded at UBS to neutral from buy. $41 price target. Company's transition will take time, UBS said.
Verizon (VZ) was upgraded at Nomura from neutral to buy. $50 price target. Company has superior execution and can continue to grow, Nomura said.
Williams-Sonoma (WSM) was upgraded at Morgan Stanley from equal-weight to overweight. $54 price target. Business is improving and the company can post double-digit annual growth over the next few years, Morgan Stanley said.
Woodward (WWD) was downgraded at Drexel Hamilton to hold. Valuation call, Drexel said.STOCK COMMENTS / EPS CHANGES
Albemarle (ALB) target raised at Jefferies tO $77, Jefferies said. Improvements in end markets. Buy rating. Ametek (AME) numbers raised at Jefferies. Shares of AME now seen reaching $44, Jefferies said. Estimates also raised 2013 productivity goal large. Buy rating. FedEx (FDX) numbers lowered at Citigroup. Shares of FDX now seen reaching $103, Citigroup said. Estimates also lowered as express headwinds persist. Buy rating. Huntsman (HUN) estimates lowered at UBS through 2013, UBS said. Softer 4Q expected by company. Buy rating and $16 price target. Teva (TEVA) estimates, target reduced at Credit Suisse. Shares of TEVA now seen reaching $50, according to Credit Suisse. Estimates also cut, given the company's new guidance. Outperform rating. Thoratec (THOR) added to Conviction Buy List at Goldman. Estimates also boosted, as the company can gain market share. $48 price target. Toll Brothers (TOL) target raised at Citigroup to $34 to reflect peer multiple expansion, Citigroup said. Neutral rating. >To submit a news tip, email: tips@thestreet.com.Follow TheStreet on Twitter and become a fan on Facebook.
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
TheStreet Quant Ratings
TRY IT FREENew! $49.95/yr
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Product Features:
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Dividend Stock Advisor
TRY IT FREEJim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
